Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases.

Paroni G, Bolis M, Zanetti A, Ubezio P, Helin K, Staller P, Gerlach LO, Fratelli M, Neve RM, Terao M, Garattini E.

Oncogene. 2018 Dec 11. doi: 10.1038/s41388-018-0620-6. [Epub ahead of print]

PMID:
30538297
2.

S100A3 a partner protein regulating the stability/activity of RARα and PML-RARα in cellular models of breast/lung cancer and acute myeloid leukemia.

Gianni M, Terao M, Kurosaki M, Paroni G, Brunelli L, Pastorelli R, Zanetti A, Lupi M, Acquavita A, Bolis M, Fratelli M, Rochette-Egly C, Garattini E.

Oncogene. 2018 Dec 7. doi: 10.1038/s41388-018-0599-z. [Epub ahead of print]

PMID:
30532072
3.

BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.

Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.

Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31898. [Epub ahead of print]

PMID:
30259975
4.

Massive NGS data analysis reveals hundreds of potential novel gene fusions in human cell lines.

Gioiosa S, Bolis M, Flati T, Massini A, Garattini E, Chillemi G, Fratelli M, Castrignanò T.

Gigascience. 2018 Oct 1;7(10). doi: 10.1093/gigascience/giy062.

5.

Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions.

Takaoka N, Sanoh S, Okuda K, Kotake Y, Sugahara G, Yanagi A, Ishida Y, Tateno C, Tayama Y, Sugihara K, Kitamura S, Kurosaki M, Terao M, Garattini E, Ohta S.

Biochem Pharmacol. 2018 Aug;154:28-38. doi: 10.1016/j.bcp.2018.04.017. Epub 2018 Apr 17.

PMID:
29678521
6.

Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.

Celestini V, Tezil T, Russo L, Fasano C, Sanese P, Forte G, Peserico A, Lepore Signorile M, Longo G, De Rasmo D, Signorile A, Gadaleta RM, Scialpi N, Terao M, Garattini E, Cocco T, Villani G, Moschetta A, Grossi V, Simone C.

Cell Death Dis. 2018 Feb 14;9(2):231. doi: 10.1038/s41419-018-0336-0.

7.

The therapeutic potential of cystathionine gamma-lyase in temporomandibular inflammation-induced orofacial hypernociception.

Santos BM, Garattini EG, Branco LGS, Leite-Panissi CRA, Nascimento GC.

Physiol Behav. 2018 May 1;188:128-133. doi: 10.1016/j.physbeh.2018.02.007. Epub 2018 Feb 6.

PMID:
29425970
8.

The autophagy scaffold protein ALFY is critical for the granulocytic differentiation of AML cells.

Schläfli AM, Isakson P, Garattini E, Simonsen A, Tschan MP.

Sci Rep. 2017 Oct 11;7(1):12980. doi: 10.1038/s41598-017-12734-4.

9.

Generation of a new mouse model of glaucoma characterized by reduced expression of the AP-2β and AP-2δ proteins.

Barzago MM, Kurosaki M, Fratelli M, Bolis M, Giudice C, Nordio L, Cerri E, Domenici L, Terao M, Garattini E.

Sci Rep. 2017 Sep 11;7(1):11140. doi: 10.1038/s41598-017-11752-6.

10.

Direct Comparison of the Enzymatic Characteristics and Superoxide Production of the Four Aldehyde Oxidase Enzymes Present in Mouse.

Kücükgöze G, Terao M, Garattini E, Leimkühler S.

Drug Metab Dispos. 2017 Aug;45(8):947-955. doi: 10.1124/dmd.117.075937. Epub 2017 May 19.

11.

Structural basis for the role of mammalian aldehyde oxidases in the metabolism of drugs and xenobiotics.

Romão MJ, Coelho C, Santos-Silva T, Foti A, Terao M, Garattini E, Leimkühler S.

Curr Opin Chem Biol. 2017 Apr;37:39-47. doi: 10.1016/j.cbpa.2017.01.005. Epub 2017 Jan 24. Review.

PMID:
28126656
12.

Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid.

Bolis M, Garattini E, Paroni G, Zanetti A, Kurosaki M, Castrignanò T, Garattini SK, Biancardi F, Barzago MM, Gianni' M, Terao M, Pattini L, Fratelli M.

Ann Oncol. 2017 Mar 1;28(3):611-621. doi: 10.1093/annonc/mdw660.

13.

Mouse aldehyde-oxidase-4 controls diurnal rhythms, fat deposition and locomotor activity.

Terao M, Barzago MM, Kurosaki M, Fratelli M, Bolis M, Borsotti A, Bigini P, Micotti E, Carli M, Invernizzi RW, Bagnati R, Passoni A, Pastorelli R, Brunelli L, Toschi I, Cesari V, Sanoh S, Garattini E.

Sci Rep. 2016 Jul 26;6:30343. doi: 10.1038/srep30343.

14.

RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells.

Gianni M, Fratelli M, Bolis M, Kurosaki M, Zanetti A, Paroni G, Rambaldi A, Borleri G, Rochette-Egly C, Terao M, Garattini E.

Oncotarget. 2017 Jun 6;8(23):37041-37060. doi: 10.18632/oncotarget.10556.

15.

Structure and function of mammalian aldehyde oxidases.

Terao M, Romão MJ, Leimkühler S, Bolis M, Fratelli M, Coelho C, Santos-Silva T, Garattini E.

Arch Toxicol. 2016 Apr;90(4):753-80. doi: 10.1007/s00204-016-1683-1. Epub 2016 Feb 26. Review.

PMID:
26920149
16.

Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer.

Garattini E, Bolis M, Gianni' M, Paroni G, Fratelli M, Terao M.

Oncotarget. 2016 Jul 5;7(27):42661-42682. doi: 10.18632/oncotarget.7410. Review.

17.

Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population.

Fratelli M, Bolis M, Kurosaki M, Dori M, Guarnaccia V, Spinelli O, Alberti M, Valoti E, Pileggi S, Noris M, Remuzzi G, Rambaldi A, Terao M, Garattini E.

Leuk Lymphoma. 2016 May;57(5):1234-7. doi: 10.3109/10428194.2015.1082180. Epub 2016 Mar 2. No abstract available.

PMID:
26317246
18.

Activation of RARα induces autophagy in SKBR3 breast cancer cells and depletion of key autophagy genes enhances ATRA toxicity.

Brigger D, Schläfli AM, Garattini E, Tschan MP.

Cell Death Dis. 2015 Aug 27;6:e1861. doi: 10.1038/cddis.2015.236.

19.

Different Stability and Proteasome-Mediated Degradation Rate of SMN Protein Isoforms.

Locatelli D, Terao M, Kurosaki M, Zanellati MC, Pletto DR, Finardi A, Colciaghi F, Garattini E, Battaglia GS.

PLoS One. 2015 Jul 27;10(7):e0134163. doi: 10.1371/journal.pone.0134163. eCollection 2015.

20.

All-trans-retinoic Acid Modulates the Plasticity and Inhibits the Motility of Breast Cancer Cells: ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR (TGFβ).

Zanetti A, Affatato R, Centritto F, Fratelli M, Kurosaki M, Barzago MM, Bolis M, Terao M, Garattini E, Paroni G.

J Biol Chem. 2015 Jul 17;290(29):17690-709. doi: 10.1074/jbc.M115.638510. Epub 2015 May 27.

21.

MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells.

Fisher JN, Terao M, Fratelli M, Kurosaki M, Paroni G, Zanetti A, Gianni M, Bolis M, Lupi M, Tsykin A, Goodall GJ, Garattini E.

Oncotarget. 2015 May 30;6(15):13176-200.

22.

Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.

Centritto F, Paroni G, Bolis M, Garattini SK, Kurosaki M, Barzago MM, Zanetti A, Fisher JN, Scott MF, Pattini L, Lupi M, Ubezio P, Piccotti F, Zambelli A, Rizzo P, Gianni' M, Fratelli M, Terao M, Garattini E.

EMBO Mol Med. 2015 Jul;7(7):950-72. doi: 10.15252/emmm.201404670.

23.

Is 'bad luck' an important determinant of cancer incidence and does this concept apply to kidney tumors?

Garattini E, Tavani A.

Nephron. 2015;129(3):219-22. doi: 10.1159/000381196. Epub 2015 Mar 10.

24.

Insights into the structural determinants of substrate specificity and activity in mouse aldehyde oxidases.

Cerqueira NM, Coelho C, Brás NF, Fernandes PA, Garattini E, Terao M, Romão MJ, Ramos MJ.

J Biol Inorg Chem. 2015 Mar;20(2):209-17. doi: 10.1007/s00775-014-1198-2. Epub 2014 Oct 7.

PMID:
25287365
25.

The four aldehyde oxidases of Drosophila melanogaster have different gene expression patterns and enzyme substrate specificities.

Marelja Z, Dambowsky M, Bolis M, Georgiou ML, Garattini E, Missirlis F, Leimkühler S.

J Exp Biol. 2014 Jun 15;217(Pt 12):2201-11. doi: 10.1242/jeb.102129. Epub 2014 Apr 15.

26.

Retinoids and breast cancer: from basic studies to the clinic and back again.

Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, Gianni' M, Zanetti A, Pagani A, Fisher JN, Zambelli A, Terao M.

Cancer Treat Rev. 2014 Jul;40(6):739-49. doi: 10.1016/j.ctrv.2014.01.001. Epub 2014 Jan 18. Review.

PMID:
24480385
27.

Aldehyde oxidase and its importance in novel drug discovery: present and future challenges.

Garattini E, Terao M.

Expert Opin Drug Discov. 2013 Jun;8(6):641-54. doi: 10.1517/17460441.2013.788497. Epub 2013 Apr 9. Review.

PMID:
23565746
28.

Structure and evolution of vertebrate aldehyde oxidases: from gene duplication to gene suppression.

Kurosaki M, Bolis M, Fratelli M, Barzago MM, Pattini L, Perretta G, Terao M, Garattini E.

Cell Mol Life Sci. 2013 May;70(10):1807-30. doi: 10.1007/s00018-012-1229-5. Epub 2012 Dec 21.

PMID:
23263164
29.

New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: the role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome.

Fratelli M, Fisher JN, Paroni G, Di Francesco AM, Pierri F, Pisano C, Godl K, Marx S, Tebbe A, Valli C, Gianni M, Stravalaci M, Gobbi M, Terao M, Garattini E.

Eur J Cancer. 2013 Apr;49(6):1491-500. doi: 10.1016/j.ejca.2012.11.013. Epub 2012 Dec 11.

PMID:
23245330
30.

The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity.

Coelho C, Mahro M, Trincão J, Carvalho AT, Ramos MJ, Terao M, Garattini E, Leimkühler S, Romão MJ.

J Biol Chem. 2012 Nov 23;287(48):40690-702. doi: 10.1074/jbc.M112.390419. Epub 2012 Sep 27.

31.

Retinoids and breast cancer: new clues to increase their activity and selectivity.

Garattini E, Paroni G, Terao M.

Breast Cancer Res. 2012 Sep 4;14(5):111. doi: 10.1186/bcr3245.

32.

Human axonal survival of motor neuron (a-SMN) protein stimulates axon growth, cell motility, C-C motif ligand 2 (CCL2), and insulin-like growth factor-1 (IGF1) production.

Locatelli D, Terao M, Fratelli M, Zanetti A, Kurosaki M, Lupi M, Barzago MM, Uggetti A, Capra S, D'Errico P, Battaglia GS, Garattini E.

J Biol Chem. 2012 Jul 27;287(31):25782-94. doi: 10.1074/jbc.M112.362830. Epub 2012 Jun 5.

33.

Adult cystic fibrosis care in the 21st century.

Garattini E, Bilton D, Cremona G, Hodson M.

Monaldi Arch Chest Dis. 2011 Sep;75(3):178-84. Review.

34.

p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells.

Gianni M, Peviani M, Bruck N, Rambaldi A, Borleri G, Terao M, Kurosaki M, Paroni G, Rochette-Egly C, Garattini E.

Leukemia. 2012 Aug;26(8):1850-61. doi: 10.1038/leu.2012.50. Epub 2012 Feb 22.

PMID:
22354283
35.

The role of aldehyde oxidase in drug metabolism.

Garattini E, Terao M.

Expert Opin Drug Metab Toxicol. 2012 Apr;8(4):487-503. doi: 10.1517/17425255.2012.663352. Epub 2012 Feb 16. Review.

PMID:
22335465
36.

Spinal muscular atrophy pathogenic mutations impair the axonogenic properties of axonal-survival of motor neuron.

Locatelli D, d'Errico P, Capra S, Finardi A, Colciaghi F, Setola V, Terao M, Garattini E, Battaglia G.

J Neurochem. 2012 May;121(3):465-74. doi: 10.1111/j.1471-4159.2012.07689.x. Epub 2012 Mar 14.

37.

The impact of single nucleotide polymorphisms on human aldehyde oxidase.

Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, Leimkühler S.

Drug Metab Dispos. 2012 May;40(5):856-64. doi: 10.1124/dmd.111.043828. Epub 2012 Jan 25. Erratum in: Drug Metab Dispos. 2016 Mar;44(3):365.

38.

Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.

Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao M, Garattini E.

Oncogene. 2012 Jul 19;31(29):3431-43. doi: 10.1038/onc.2011.506. Epub 2011 Nov 7.

PMID:
22056878
39.

Characterization and crystallization of mouse aldehyde oxidase 3: from mouse liver to Escherichia coli heterologous protein expression.

Mahro M, Coelho C, Trincão J, Rodrigues D, Terao M, Garattini E, Saggu M, Lendzian F, Hildebrandt P, Romão MJ, Leimkühler S.

Drug Metab Dispos. 2011 Oct;39(10):1939-45. doi: 10.1124/dmd.111.040873. Epub 2011 Jun 24.

40.

Increasing recognition of the importance of aldehyde oxidase in drug development and discovery.

Garattini E, Terao M.

Drug Metab Rev. 2011 Aug;43(3):374-86. doi: 10.3109/03602532.2011.560606. Epub 2011 Mar 23. Review.

PMID:
21428696
41.

Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets.

Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia V, Paroni G, Tsykin A, Lupi M, Gianni M, Goodall GJ, Garattini E.

J Biol Chem. 2011 Feb 4;286(5):4027-42. doi: 10.1074/jbc.M110.184994. Epub 2010 Dec 3.

42.

Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.

Binaschi M, Boldetti A, Gianni M, Maggi CA, Gensini M, Bigioni M, Parlani M, Giolitti A, Fratelli M, Valli C, Terao M, Garattini E.

ACS Med Chem Lett. 2010 Jul 20;1(8):411-5. doi: 10.1021/ml1001163. eCollection 2010 Nov 11.

43.

The mammalian aldehyde oxidase gene family.

Garattini E, Fratelli M, Terao M.

Hum Genomics. 2009 Dec;4(2):119-30.

44.

Multiple drug hypersensivity: insight into the underlying mechanism and correlation with autoimmune diseases.

Colombo G, Yacoub MR, Burastero SE, Garattini E, Girlanda S, Saporiti N, Salvo F, Sabbadini MG.

Eur Ann Allergy Clin Immunol. 2009 Apr;41(2):50-5.

PMID:
19585860
45.

Site directed mutagenesis of amino acid residues at the active site of mouse aldehyde oxidase AOX1.

Schumann S, Terao M, Garattini E, Saggu M, Lendzian F, Hildebrandt P, Leimkühler S.

PLoS One. 2009;4(4):e5348. doi: 10.1371/journal.pone.0005348. Epub 2009 Apr 29.

46.

Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha.

Gianni' M, Boldetti A, Guarnaccia V, Rambaldi A, Parrella E, Raska I Jr, Rochette-Egly C, Del Sal G, Rustighi A, Terao M, Garattini E.

Cancer Res. 2009 Feb 1;69(3):1016-26. doi: 10.1158/0008-5472.CAN-08-2603. Epub 2009 Jan 20.

47.

SUG-1 plays proteolytic and non-proteolytic roles in the control of retinoic acid target genes via its interaction with SRC-3.

Ferry C, Gianni M, Lalevée S, Bruck N, Plassat JL, Raska I Jr, Garattini E, Rochette-Egly C.

J Biol Chem. 2009 Mar 20;284(12):8127-35. doi: 10.1074/jbc.M808815200. Epub 2009 Jan 13.

48.

Role of the molybdoflavoenzyme aldehyde oxidase homolog 2 in the biosynthesis of retinoic acid: generation and characterization of a knockout mouse.

Terao M, Kurosaki M, Barzago MM, Fratelli M, Bagnati R, Bastone A, Giudice C, Scanziani E, Mancuso A, Tiveron C, Garattini E.

Mol Cell Biol. 2009 Jan;29(2):357-77. doi: 10.1128/MCB.01385-08. Epub 2008 Nov 3.

49.

Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity.

Valli C, Paroni G, Di Francesco AM, Riccardi R, Tavecchio M, Erba E, Boldetti A, Gianni' M, Fratelli M, Pisano C, Merlini L, Antoccia A, Cenciarelli C, Terao M, Garattini E.

Mol Cancer Ther. 2008 Sep;7(9):2941-54. doi: 10.1158/1535-7163.MCT-08-0419.

50.

Mammalian aldehyde oxidases: genetics, evolution and biochemistry.

Garattini E, Fratelli M, Terao M.

Cell Mol Life Sci. 2008 Apr;65(7-8):1019-48. Review.

PMID:
18066686

Supplemental Content

Loading ...
Support Center